Académique Documents
Professionnel Documents
Culture Documents
By
Tansakul M. , Yutchawit P.
Under supervision of …
Wiwatthanachang O.
Portal hypertension =
portal pressure gradient >5
mmHg
Clinically significant
portal hypertension
>= 10 mmHg.
Increase resistance in
hepatic circulation Increase portal
blood flow
Medications associated with idiopathic
noncirrhotic portal hypertension
• Azathiopine
• Cyclophosphamide
• Doxurubicin
• Bleomycin
Complication of portal hypertension
• Variceal hemorrhage
• Hepatopulmonary syndrome
• Portopulmonary hypertension
• Cirrhotic cardiomyopathy
Variceal hemorrhage : prophylaxis
• Primary prophylaxis
• Secondary prophylaxis
Variceal hemorrhage : Primary
prophylaxis
• Endoscopy of all patient with cirrhosis if normal follow up q 2-3
years
• Non selective Beta blocker (propranolol, carvedilol)
• Esophageal variceal band ligation
• Transjugular intrahepatic portosystemic shunt
Drug : variceal bleeding
• Splanchnic vasoconstriction
• Somatostatin 250 mcg iv bolus, then drip 250 mcg/hr 3-5 days
• Octreotide 50 mcg iv bolus, then drip 50 mcg/hr
• Terlipressin 0.5-2 mg iv q 4 hr in 48 hr then 1 mg iv in q 4 hr (Caution in
CAD,PVD)
• Antibiotic prophylaxis
• Norfloxacin 400 mg bid x 7 days (ciprofloxacin)
• IV ceftriaxone 1 g/day x 7 days ( in child B-C, NPO)
Secondary prevention
Concise and practical point
Definition of ‘Ascites’
•Accumulation of fluid within peritoneal cavity.
•Most common cause = portal HT
•Other cause = malignant , infection
Cirrhosis - 81%
Cancer - 10%
Heart Failure - 3%
Tuberculosis - 2%
Dialysis - 1%
Pancreatic Disease - 1%
Other - 2%
Pathogenesis
Figure 41-2
Harrison’s
Gastroenterology
And hepatology
17th Edition
Clinical presentation
•Abdominal girth
•Peripheral edema
•Compromised respiratory function
• Hepatic hydrothorax
• Other unspecific symptom and fatigue / malnourished
Diagnosis
•Physical examination
•Abdominal imaging ; U/S or CT abdomen
•Abdominal paracentesis
… for total protein, albumin, cell diff and count,
G/S, C/S (in some setting –amylase, cytology)
SAAG ;
Serum ascites-to-albumin gradient
•Cut point is 1.1
•Transudate vs exudate
Portal cause
Non-Portal cause
Ascites Profile
•SAAG
•Very low ascites protein
>> increased risk of developing SBP
•High level of RBC
>> Trauma ?, HCC ?, rupture omental varix?
•PMN count > 250 cell/mm 3
>> Infection ?
Treatment of ascites
• Salt restriction !! ( < 2 g /day or 88 mmol/day)
+ water restriction (1-1.5l/day)
•Weight measurement ***
• Diuretics (Na excretion > 78 mmol/day)
• Spironolactone100-200 mg (max 400 mg/day)
• Combination with furosemide 20-40 mg (max 160mg/day)
This graphic shows that the addition of albumin to cefotaxime clearly prevented
renal impairment and improved mortality when compared with cefotaxime alone.
p values: renal impairment p=0.002, in-hospital mortality p=0.01, 3 month
mortality p=0.03
Sort P, Navasa M, Arroyo V, et al. N Engl J Med. 1999;341:403-9
American Association for the Study of Liver Diseases (AASLD) 2012
** SBP prophylaxis ; Why ?
•Cirrhotic patient with ascites or previous SBP
have high recurrent rate. (70%)
•High mortality rate of SBP
(9 mo of mean survival time)
•Selective intestinal decontamination
•Increased risk of drug resistant ?
** SBP prophylaxis ; When ?
•Primary prophylaxis
•Cirrhotic ascites with GI hemorrhage
•Cirrhotic ascites with LOW protein in ascites
(<1.5g/dl) + Cr > 1.2 mg/dl or BUN > 25 mg/dl
or serum Na <130 mEQ/l
•Cirrhosis with Child Pugh score > 9 (Child C) +
serum TB > 3 mg/dl
•Secondary prophylaxis
•Hx of previous SBP
•Acidic pH helps..
• Leeching NPH3
• Decreased harmful bacteria proliferation ;
decreased NH3 production
• Decreased NH3 >> NH4 conversion.
Summary points for HE
• Overt
hepatic encephalopathy consists of neurological and psychiatric
abnormalities that can be detected by bedside clinical tests, whereas
minimal hepatic encephalopathy can only be distinguished by specific
psychometric tests.
• There are many grading scales available for hepatic encephalopathy,
including the long standing West Haven Criteria, which is the most
commonly used system.
• Diagnosis of overt hepatic encephalopathy requires the exclusion of
alternate causes of altered mental status. Serum ammonia levels
should not be used as a diagnostic tool or as a means of monitoring
response to treatment.
• Treatment of acute overt hepatic encephalopathy should include: (1)
supportive care, (2) identifying and treating any precipitating factors,
(3) reduction of nitrogenous load in the gut, and (4) assessment of need
for long-term therapy and liver transplant evaluation.
Summary points for HE
• Lactulose can be used as initial drug therapy for the treatment of acute
hepatic encephalopathy. Rifaximin should be added for those patients
who do not have an adequate response to lactulose. Subsequently, the
addition of oral branched-chain amino acids or intravenous L-ornithine-
L-aspartate can be considered in patients who do not respond to the
combination of lactulose and rifaximin.
• Prevention of recurrent hepatic encephalopathy or treatment of persistent
hepatic encephalopathy includes drug therapy as well as prevention or
avoidance of precipitating factors.
• Proteinrestriction should be avoided as a general rule, as it can actually
lead to worsening of hepatic encephalopathy. Cirrhotic patients are
advised to consume 1.25 to 1.5 g/kg protein daily.
• Livertransplant evaluation should be considered in appropriate
candidates once a diagnosis of overt hepatic encephalopathy is made.
Liver transplantation is indicated in patients who have liver failure and
recurrent intractable overt hepatic encephalopathy.
Reference